A Study Evaluating Safety, Pharmacokinetics, and Therapeutic Activity of RO6874281 as a Single Agent (Part A) or in Combination With Trastuzumab or Cetuximab (Part B or C)

NCT02627274 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

134

Enrollment

INDUSTRY

Sponsor class

Conditions

Solid Tumor
Breast Cancer
Cancer of Head and Neck

Interventions

DRUG: RO6874281
DRUG: Trastuzumab
DRUG: Cetuximab

Sponsor

Hoffmann-La Roche